Immucell (ICCC) Net Equity Issued and Repurchased (2017 - 2025)

Immucell (ICCC) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $329892.0 in Q2 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $329892.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $349326.0 (down 98.87% YoY) and the FY2025 annual result came in at $349326.0, down 92.48% from the prior year.
• Net Equity Issued and Repurchased improved to $329892.0 in Q2 2025, from $19434.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $26.7 million in Q1 2023 to a low of -$4.2 million in Q2 2021.
• A 5-year average of $4.9 million and a median of $153644.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 50.0% — and 2023, when it surged 457338.41%.
• Tracing ICCC's Net Equity Issued and Repurchased over 5 years: stood at $153644.0 in 2021, then surged by 17266.98% to $26.7 million in 2022, then rose by 0.12% to $26.7 million in 2023, then tumbled by 97.98% to $539292.0 in 2024, then sank by 38.83% to $329892.0 in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $329892.0 (Q2 2025), $19434.0 (Q1 2025), and $539292.0 (Q4 2024), per Business Quant data.